Altanine

Executive Summary

Altanine is a preclinical-stage biotechnology company based in San Diego, California, focused on developing novel small molecule therapeutics that target protein-protein interactions (PPIs) in oncology and other diseases. Founded in 2018, the company leverages a proprietary platform to design inhibitors against previously undruggable targets, addressing high unmet medical needs. Altanine operates with a lean team of 50–200 employees and has maintained a low public profile, with limited disclosure of financials or specific pipeline assets. Its technology holds potential across multiple cancer types, but the company remains in the early discovery and lead optimization phase, typical for companies at this stage. As a private preclinical entity, Altanine faces significant development and regulatory risks, though its focus on PPIs—a validated but challenging class—positions it for potential partnerships or milestone-driven growth. The company's near-term value drivers include IND-enabling studies, initial candidate selection disclosures, or licensing deals. Given the lack of public pipeline data and the inherent uncertainty of preclinical research, the conviction score is moderate. Key catalysts to watch include the announcement of a lead candidate, IND filing, or strategic collaboration, which could occur within the next 12–18 months.

Upcoming Catalysts (preview)

• Q3 2026Lead candidate nomination for oncology PPI program60% success
• Q1 2027IND filing for first clinical candidate30% success
• Q2 2027Partnership or licensing deal with larger pharma25% success